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Chronic obstructive pulmonary disease (COPD) is a debilitating disease affecting patients in daily life, both physically
and emotionally. Symptoms such as dyspnea and muscle fatigue, lead to exercise intolerance, which, together with
behavioral issues, trigger physical inactivity, a key feature of COPD. Physical inactivity is associated with adverse
clinical outcomes, including hospitalization and all-cause mortality. Increasing activity levels is crucial for effective
management strategies and could lead to improved long-term outcomes. In this review we summarize objective and
subjective instruments for evaluating physical activity and focus on interventions such as pulmonary rehabilitation or
bronchodilators aimed at increasing activity levels. To date, only limited evidence exists to support the effectiveness of
these interventions. We suggest that a multimodal approach comprising pulmonary rehabilitation, pharmacotherapy,
and counselling programs aimed at addressing emotional and behavioural aspects of COPD may be an effective way
to increase physical activity and improve health status in the long term.
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Chronic obstructive pulmonary disease (COPD) is a
debilitating and progressive disease that primarily affects
the respiratory system. In many patients, it also has
detrimental extra-pulmonary effects, such as weight loss
and skeletal muscle dysfunction/wasting [1]. The pulmonary
and skeletal muscle abnormalities limit the pulmonary
ventilation and enhance the ventilatory requirements
during exercise resulting in exercise-associated symptoms
such as dyspnea and fatigue. These symptoms make
exercise an unpleasant experience, which many patients
try to avoid, and along with a depressive mood status (in
up to 30% of patients), further accelerates the process,
leading to an inactive life-style. Muscle deconditioning,
associated with reduced physical activity, contributes to
further inactivity and as a result patients get trapped in
a vicious cycle of declining physical activity levels and
increasing symptoms with exercise (Figure 1) [1-3].* Correspondence: Thierry.Troosters@med.kuleuven.be
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reproduction in any medium, provided the orPhysical activity levels are remarkably lower in stable
outpatients with COPD than in healthy individuals [4-6];
even in patients with early-stages disease [7-9]. At a
group level, increasing severity of COPD is associated
with decreasing physical activity [9]. Physical activity
level is recognized as a predictor of mortality and
hospitalization in patients with COPD and contributes to
disease progression and poor outcomes [10]. Increasing
activity levels may improve long-term outcomes as seen
in other chronic conditions such as diabetes [11].
This review will summarize the characteristics of in-
struments used to assess physical activity in COPD and
discuss the important implications of physical inactivity
in this context, with a particular focus on interventions
aimed at helping patients become more physically active
in daily life. The review was based on a literature search of
the PubMed database (no date limits) for COPD and
terms relating to exercise and physical activity.Physical activity levels recommendation and applications
in COPD
The recently developed World Health Organization (WHO)
guidelines for physical activity recommend that all adults
should undertake at least 150 minutes of moderate-intensityal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 The vicious cycle of inactivity and symptoms.
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a healthy lifestyle [12]. Individuals limited by medical
conditions are advised to undertake as much physical
activity as their health allows. A joint statement from the
American Thoracic Society and the European Respiratory
Society in 2006 states that pulmonary rehabilitation
‘should no longer be viewed as a “last ditch” effort for
patients with severe respiratory impairment. Rather, it
should be an integral part of the clinical management
of all patients with chronic respiratory disease, addressing
their functional and/or psychologic deficits’ [13]. An
update of this document, recently accepted for publication,
will further stress the importance of physical activity and
improvement of physical activity as a goal for pulmonary
rehabilitation. The more recent 2013 Global Initiative
for Chronic Obstructive Lung Disease (GOLD) strategy
recommends that all patients with COPD should partici-
pate in daily physical activity, although recommended
levels have not been defined [2]. Despite these recommen-
dations, a recent Swedish study demonstrated that signifi-
cantly fewer patients with COPD attained recommended
physical activity levels compared with a healthy population
and patients with other chronic diseases, such as rheuma-
toid arthritis or diabetes [14].Evaluation of physical activity
It is important to make the distinction between physical
activity and exercise capacity, which are both closely
related to clinical outcomes in COPD. Physical activity is
‘any bodily movement produced by skeletal muscles that
results in energy expenditure’ [15]. By contrast, exercise
capacity indicates an individual’s ability to endure exercise,
where exercise comprises physical activities that are
specifically performed with the intention of improving
physical fitness. Exercise capacity indicates what a person
is capable of doing, while physical activity reflects what
someone actually does.
Physical activity can be assessed by direct observation,
evaluation of energy expenditure during bodily movement,
physical activity questionnaires and patient diaries, andthe use of performance based motion sensors. Direct
observation is a time-consuming and intrusive method,
and therefore not suitable for assessing physical activity
in large populations [16]. Energy spent on physical
activities can be assessed by indirect calorimetry such
as the doubly labeled water method [17]; however,
body mass, movement efficiency, and the energy cost of
activities, make inter-individual comparison of the amount
of physical activity performed difficult. Furthermore, the
quantity, duration, frequency and intensity of physical
activity cannot be discriminated. Moreover, patients with
COPD have a poor mechanical efficiency yielding larger
energy expenditure compared to healthy subjects for the
same level of activity [18].Subjective instruments for assessing physical activity
Specifically designed questionnaires and diaries are sub-
jective measures that have been used to quantify physical
activity in daily life [19,20]. These tools are helpful for
evaluating the patients’ perspectives on their ability to
carry out daily activities. Self-reported questionnaires
and diaries rely on memory and recall of the patients
[21,22] and several variables such as the design of the
questionnaire [23], patient characteristics (age, cognitive
capacity, cultural factors) [16,21,24] and interviewer char-
acteristics [16] may affect the reliability of the results. It
has been shown that patients’ estimation of time spent on
physical activities in daily life disagreed with objective
assessment [25].
The most frequently used subjective tools with a
better-documented validation include the Minnesota Leisure
Time Physical Activity Questionnaire (MLTPAQ) or Survey
(MLTPAS) [26], the Baecke Physical Activity Questionnaire
[27,28], Follick’s diary [29], the Physical Activity Scale for the
Elderly (PASE) [30,31] and the Zutphen Physical Activity
Questionnaire (ZPAQ) [32]. A recent study in which
the utility of four questionnaires was compared against
accelerometry in COPD found the Stanford to be more
reliable than the PASE, Zutphen or Baecke [33]. Unfor-
tunately the association between measured PA and the
questionnaires outcomes was poor for all questionnaires.
Web-based applications, which require less time than
paper-based questionnaires to be completed by patients,
have also been developed [34]. A unique project aimed
at developing and validating patient reported outcome
tools to investigate dimensions of physical activity that
are judged as being essential by patients, is currently
underway (PROactive; physical activity as a crucial patient
reported outcome in COPD) and is due to be completed
in 2014 [12]. This project is exploring the development
of tools that will capture daily physical activity from the
patient perspective to reflect their experiences of physical
activity.
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Figure 2 Regular physical activity reduces hospital admissions
(upper panel A) and all-cause death (lower panel B) [50].
Kaplan-Meier curves according to level of regular physical activity
during follow-up. Patients with COPD from the Copenhagen City Heart
Study (n=2386), recruited from 1981 and followed to 2000. Reproduced
from [50] with permission from BMJ Publishing Group Ltd.
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The clinical evaluation and validation of objective measures
of assessing physical activity continues to be investigated.
The PROactive project has identified available physical
activity monitors [35]. Motion sensors, which include
pedometers used for measuring steps and accelerometers
used for detecting body acceleration, can be used for the
objective quantification of physical activity over time [16].
Although pedometers may underestimate the amount of
physical activity, particularly slow-walking [36], and offer
no information on the pattern of physical activity or the
time spent in different activities [37], several studies have
shown that they can capture physical activity in patients
with COPD [38-40].
Accelerometers are electronic devices, generally worn
on the arm (multisensory armband devices) or waist, which
estimate physical activity outcomes such as body posture,
quantity and intensity of body movements, energy expend-
iture, and physical activity level based on measurements of
body’s acceleration [41].
Evidence for the reliability, validity and responsiveness
of accelerometers is still limited in the COPD population
[9,16]. Accelerometers are also limited by the cost, poor
patient acceptance of some models [42], sensitivity to
artefacts [16], observation bias [43] and compliance issues
[43]. However, a recent multicentre study reported good
compliance with wearing the devices and limited technical
problems [44]. Despite these limitations, two recent
studies [45,46] provide a framework to validate activity
monitors for use in patients with chronic disease, evaluat-
ing compliance, usability, validity in the field setting and
in a laboratory setting. Three of six monitors tested met
all prespecified validity criteria and can be used to assess
physical activity levels of patients with COPD. Physical
activity is variable from day to day, which is a challenge
to clinical trial designs. More studies elaborating on how
physical activity monitor outcomes can be assessed and
reported is needed. Guidance is available from a recent
series of papers endorsed by the American College of
Sports Medicine [47].
Implications of physical inactivity in COPD
Physical inactivity is one of the most potent predictors
of mortality in COPD [48,49]. A population-based study
found that all levels of regular physical activity were
associated with an adjusted lower risk of all-cause mortal-
ity and respiratory mortality (Figure 2) [50]. Low levels
of physical activity have been associated with a higher
risk of hospitalization and re-hospitalization [48,50,51].
In a prospective study in 173 patients with moderate-to-
very severe COPD, patients with low physical activity
levels (measured objectively) had a shorter time to first
COPD admission versus those with higher activity levels
[48]. Patients are particularly inactive during and afterhospitalization for an acute exacerbation, and physical
inactivity soon after discharge has been shown to increase
the probability of readmission within the following
year [52].
It has been shown that the level of physical activity is
the most important factor in determining self-rated
general health and HRQoL in patients with COPD, with
the most physically active patients reporting the best
health and HRQoL [4,53]. Over a five year study period,
patients who maintained moderate or high levels of
physical activity or increased their physical activity had
an improved HRQoL, and patients who had a low level
of physical activity experienced significant declines in
HRQoL [53]. Further, a cross-sectional, survey-based
study with over 1500 patients with COPD reported that
the probability of having better self-rated general health
increased 2.4–7.7-fold and the likelihood of experiencing
psychological distress declined by around 50% with
higher physical activity levels [4]. Overall, patients with
COPD who are more physically active have generally
better functional status in terms of diffusing capacity of
the lung carbon monoxide, expiratory muscle strength,
exercise capacity, maximal oxygen uptake and systemic
inflammation, compared with those who are less active [10].
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and meaningful patient outcomes, improving physical
activity levels is an important goal in the management of
COPD.
Interventions to improve physical activity
Pulmonary rehabilitation and the modification of
patient behavior
Pulmonary rehabilitation (PR) aims to break the vicious
cycle illustrated in Figure 1. PR programs are multidis-
ciplinary programs that are built around an exercise
training intervention. Exercise training aims to reverse
the systemic consequences of COPD, in particular the
skeletal muscle dysfunction, enhances the mechanical
efficiency of physical activities (particularly walking) and
reduces the sensitivity to dyspnea [54] and the ventilation
required to overcome a specific task [55]. PR also appears
to have a beneficial effect on patients’ experience of
physical activity, e.g. by reducing fear and allowing
them to increase activities [56].
PR programs have shown varying results with respect
to their effect on physical activity. Three studies, both
short-term (3 weeks) and longer-term (6–12 weeks) did
not find an increase in the level of physical activity
after the PR programs [57-59]. However, three studies
reported a significant increase in physical activity after
PR for the same duration [60-62]. Issues regarding the
measurement properties of the activity monitors, the
best site (or sites) to wear the motion detectors, and
the optimal variable to analyze (movement intensity/
duration, estimated steps, estimated energy expenditure,
etc.) may all play a role. Only recently have studies of
these motion detector devices in COPD begun to emerge
[45,46]. Although exercise training may confer a signifi-
cant increase in physical activities [63], these improve-
ments are smaller than expected if considering that
exercise training can result in a substantial increase in
exercise endurance [8].
In healthy subjects, behavioral and environmental factors
are associated with physical activity levels (Reviewed in
Bauman et al. [64]). It has been hypothesized that the
reduced physical activity levels in patients with COPD
may potentially have a behavioral element and some
patients may opt to limit their activity levels rather
than be restricted by their symptoms [65]. In a study
with COPD patients, a counseling program that used
pedometers to monitor and motivate patients to increase
their level of physical activity was offered to a group of
out-clinic patients [39]. After 12 weeks, the patients who
received counseling showed a significant increase in the
number of steps per-day and a significant improvement in
arm and leg strength, HRQoL, and changes in intrinsic
motivation score to be physically active compared with
patients who received usual care. Other studies haveshown that counseling programs and pulmonary rehabili-
tation or structured exercise programs can be comple-
mentary [38,66]. More recently internet based programs
have found their way to the COPD population [67]. These
programs provide feedback to patients and may foster
the creation of social networks that invite to be physic-
ally active.Pharmacotherapy
Dynamic hyperinflation, which is associated with reduced
physical activity levels [68,69], is improved with broncho-
dilator therapy [70], indicating indirectly that bronchodila-
tion could result in increased physical activity. Indeed, this
had been suggested by Casaburi et al. in a trial assessing
the effect of tiotropium on exercise endurance. Patients
receiving tiotropium showed significantly longer exercise
endurance time at the conclusion of pulmonary rehabilita-
tion compared to patients in the placebo control group
[71]. Notably, a following study suggested that tiotropium
could amplify the effectiveness of pulmonary rehabilitation
as shown by the increase in patient self-reported participa-
tion in physical activities. A subsequent sub-analysis of the
Understanding Potential Long-term Impacts on Lung
Function with Tiotropium (UPLIFT) trial indicated that
therapy with tiotropium was effective in improving the
QoL of patients with COPD, particularly with regard to
the SGRQ domain of physical activity [72].
Compared with a control group, tiotropium amplified
the effectiveness of PR in patients with severe and very-
severe COPD as demonstrated by increases in patient
self-reported participation in physical activities outside
the PR program [73]. A recent study investigated the
impact of tiotropium added to budesonide/formoterol
(combination of inhaled corticosteroid and long-acting
beta-2 agonist) in patients with COPD [74]. Significant
improvements were observed in the morning activities
as assessed by the Capacity of Daily Living during the
Morning (CDLM) questionnaire (total score and for indi-
vidual questions) with tiotropium added to budesonide/
formoterol compared with tiotropium alone (Figure 3).
This finding is of particular interest in COPD since patients
report that morning symptoms are most challenging and
heavily impact social and physical activities [75].
Results from a large multi-center trial designed to
evaluate the impact of pharmacologic intervention with
tiotropium on lung function and the amount of physical
activity using an activity monitoring device in patients
with GOLD stage II COPD [76] who are not receiving
maintenance therapy are awaited [77]. An additional focus
of the study will be to assess if efforts to improve physical
activity levels early in the course of the disease may
contribute to reducing the burden of the morbidity in
patients with COPD.
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Figure 3 Change in morning activities (absolute scores) over
treatment period with budesonide/formoterol plus tiotropium
versus placebo plus tiotropium [74]. CDLM: Capacity of Daily
Living during the Morning questionnaire; dotted line represents
budesonide/formoterol plus tiotropium; solid line represents placebo
plus tiotropium; CDLM score at run-in budesonide/formoterol plus
tiotropium: 4.09, placebo plus tiotropium: 4.13; †treatment comparison
from randomization to first week of treatment; ‡treatment comparison
from randomization to last week of treatment. Reprinted with
permission of the American Thoracic Society. Copyright © 2013
American Thoracic Society. Welte T, Miravitlles M, Hernandez P,
Eriksson G, Peterson S, Polanowski T, et al: Efficacy and tolerability of
budesonide/formoterol added to tiotropium in patients withchronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2009,
180:741–750. Official journal of the American Thoracic Society.
Troosters et al. Respiratory Research 2013, 14:115 Page 5 of 8
http://respiratory-research.com/content/14/1/115The way forward
As discussed, the link between bronchodilation, PR,
maximal physical performance and physical activity is
far from clear-cut. The evidence presented suggests that
PR programs may enhance physical activity, but effects
are heterogeneous across studies. Longer programs, or
the inclusion of targeted behavioral interventions may be
needed in order to ensure that patients make significant
improvements in physical activity in daily life as exercise
training alone is unlikely to alter physical activity behavior.
[78]. Nevertheless, studies conducted in patients with
mild, moderate and severe COPD have shown a positive
impact of PR programs on exercise tolerance and exercise
induced symptoms, which could potentially lead patients
to become more active in daily life [79-82]. This evidence
argues in favor of the adoption of PR in patients with a
wide range of COPD severities, including mild COPD, in
line with the GOLD 2013 recommendation [2].
Although several studies have assessed the impact of
bronchodilators on hyperinflation and exercise endurance
capacity in COPD [83-85], evidence on the impact of
bronchodilators on physical activity is still scarce. A study
in 23 COPD patients evaluating the effect of indacaterol
on physical activity measured by an accelerometer over 4
weeks suggested that bronchodilator therapy can improve
physical activity [86]. However, when activity level were
measured using a sensewear arm band device in a largerstudy conducted in 90 COPD patients, treatment with
indacaterol failed to show any significant improvement
versus placebo [87]. The duration of the treatment, dif-
ferences in the target population and sub-optimal data
processing could have played a role in the discrepancies
between the two studies. Based on existing evidence,
isolated bronchodilator therapy seems unlikely to achieve
increases in physical activity, since even PR is often
considered to have an inconsistent effect on daily physical
activity levels [88-91], unless provided for a prolonged
period [78,92]. On a conceptual level, it is possible that
bronchodilators could be effective in patients whose main
obstacle to physical activity is dyspnea. However, it is also
probable that bronchodilators have no effect on physical
activity unless combined with some sort of behavioral
intervention and/or PR. Preliminary evidence suggests that
a counseling program can increase activities of daily
living in the absence or presence of a PR program [38,39].
Further investigation to assess the extent to which this
should become a standard part of both the physical and
pharmacological therapy of COPD is warranted.
It is interesting to note that several interventions that
enhance exercise capacity do not seem to have an effect
on physical activity. This could be due to several factors
including the choice of patient inclusion criteria and
tools used to assess physical activity in clinical trials. In
designing future studies investigating physical activity in
patients with COPD, it may be desirable to stratify par-
ticipants by physical activity levels measured objectively.
As the relationship between GOLD stage and physical
activity level is ambiguous [5,9,93], direct measurement of
physical activity levels or use of a questionnaire surrogate
[33] in future studies will better aid stratification than
forced expiratory volume in one second (FEV1). In
addition, new tools able to capture physical activity
from the patient’s perspective are required. Currently
available tools measure the amount of physical activity,
but they fail to capture the full patient experience of
physical activity with regards to symptoms, which have
a considerable impact and, to a certain degree, will de-
termine to what extent patients engage in the activities.
A comprehensive patient-centered approach combining
objective information on the amount of activity with
subjective patient experience could be beneficial as it
may also help identify the barriers to physical activity
in patients with COPD. This may assist in the development
of new and comprehensive interventions with the specific
aim of increasing physical activity.
Conclusion
Physical activity is reduced in patients with COPD. This
is associated with a higher risk of hospital admission and
an increased risk of mortality, and also places patients with
COPD at risk of developing comorbidities. Importantly,
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follows that improving physical activity allows the patients
to take a productive part in daily life and may also confer
long term health benefits. The assessment of physical
activity and the interpretation of results is an area that
has garnered considerable interest. Both subjective and
objective instruments for evaluating physical activity
have advantages and disadvantages. Patient compliance,
appropriate assessment period, and accurate interpretation
of data are essential for a precise estimation of daily
physical activity. There is limited and inconsistent evidence
on the effectiveness of interventions (PR and bronchodila-
tors) for improving physical activity. These inconsistencies
may be partly due to patient choice and whether they
choose to maintain the life style options explained during
their pulmonary rehabilitation. A combination of individu-
alized PR programs and pharmacotherapy in conjunction
with behavioral modification may be the way forward to
help patients adopt a more active lifestyle.
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